Finasteride and Benzodiazepines: Drug Interaction Guide

Pharmacokinetic Overlap: The CYP3A4 Connection

Finasteride is metabolized primarily through the cytochrome P450 3A4 enzyme system, with a secondary contribution from CYP3A5. The drug carries a long elimination half-life of 5 to 6 hours in younger men and extends to 8 hours or more in men over age 70, according to the FDA-approved prescribing information for Propecia. This hepatic processing creates a point of intersection with several commonly prescribed benzodiazepines.

Not all benzodiazepines share this pathway equally. Alprazolam, midazolam, and triazolam depend heavily on CYP3A4 for their oxidative metabolism. Diazepam uses both CYP3A4 and CYP2C19. Lorazepam, oxazepam, and temazepam bypass the CYP system almost entirely, undergoing direct glucuronidation instead. A pharmacogenomics review published in Pharmacogenetics and Genomics confirmed that CYP3A4 activity significantly influences plasma concentrations of oxidatively metabolized benzodiazepines but has no measurable effect on glucuronidated agents.

The clinical question is whether finasteride, at therapeutic doses (1 mg for hair loss or 5 mg for BPH), inhibits CYP3A4 enough to raise benzodiazepine plasma levels. The answer is no, based on available evidence. Finasteride is a substrate of CYP3A4 but has not demonstrated clinically meaningful inhibitory or inductive activity at the enzyme level. The Propecia prescribing information states that finasteride does not appear to affect the cytochrome P450-linked drug metabolizing enzyme system, and no drug interactions of clinical importance have been identified.

Why the Interaction Still Matters: Neurosteroid Pharmacodynamics

The more relevant concern is pharmacodynamic, not pharmacokinetic. Finasteride blocks 5-alpha reductase type II, which converts testosterone to dihydrotestosterone. That same enzyme also converts progesterone to allopregnanolone, one of the brain's most potent endogenous positive allosteric modulators of the GABA-A receptor. Benzodiazepines bind to a separate site on the same GABA-A receptor complex.

A study by Uzunova et al. published in the Proceedings of the National Academy of Sciences demonstrated that allopregnanolone levels in cerebrospinal fluid are significantly reduced in patients with major depression, and that drugs modifying neurosteroid synthesis alter GABAergic tone. Finasteride reduces circulating allopregnanolone by approximately 50% to 60% at the 5 mg dose, as documented in research by Dusková et al. in Physiological Research.

This creates a bidirectional pharmacodynamic interaction. On one hand, reduced allopregnanolone might diminish baseline GABAergic tone, potentially making benzodiazepines feel less effective to some patients. On the other hand, the loss of endogenous GABA-A modulation may unmask anxiety or mood destabilization that leads to increased benzodiazepine use. Neither outcome represents a classic drug interaction in the hepatic metabolism sense, but both matter in clinical practice.

A small but notable body of case reports has linked finasteride to depressive symptoms and anxiety. The FDA added warnings about depression and suicidality to finasteride labels in 2012. If a patient is prescribed benzodiazepines for anxiety and simultaneously starts finasteride, clinicians should consider whether new or worsening mood symptoms reflect the neurosteroid reduction rather than treatment failure of the benzodiazepine.

Severity Rating Across Major Drug Interaction Databases

No major drug interaction database classifies the finasteride-benzodiazepine combination as contraindicated or severe. The interaction, when listed at all, receives a minor or moderate classification depending on the specific benzodiazepine.

The Lexicomp database rates finasteride interactions with CYP3A4-substrate benzodiazepines as category C (monitor therapy). Micromedex does not flag a direct interaction between finasteride and any individual benzodiazepine. The Clinical Pharmacology database maintained through the FDA's DailyMed system lists finasteride's drug interaction profile as limited, noting the absence of significant CYP450 inhibition.

This low severity rating stands in contrast to true CYP3A4 inhibitors like ketoconazole, itraconazole, or ritonavir, which can increase midazolam AUC by 10- to 15-fold. A landmark study by Greenblatt et al. in Clinical Pharmacology and Therapeutics showed that ketoconazole 400 mg daily increased midazolam AUC by 1,500%. Finasteride produces nothing comparable.

The practical takeaway: this is a combination where awareness matters more than avoidance. Most patients can take both drugs concurrently without dose modification.

Which Benzodiazepines Carry the Lowest Risk?

Benzodiazepines metabolized through glucuronidation present virtually zero pharmacokinetic interaction risk with finasteride. Three agents fall into this category.

Lorazepam undergoes direct conjugation with glucuronic acid via UGT enzymes, producing inactive metabolites excreted renally. The FDA label for lorazepam confirms no dependence on CYP450 metabolism. Oxazepam follows the same glucuronidation pathway. Temazepam is also primarily glucuronidated, though a minor oxidative pathway exists.

For patients taking finasteride who require a benzodiazepine, selecting lorazepam or oxazepam eliminates the CYP3A4 overlap entirely. This is especially relevant for older men taking finasteride 5 mg for BPH, who may have reduced hepatic CYP3A4 activity due to age. A population pharmacokinetic analysis published in the British Journal of Clinical Pharmacology confirmed that CYP3A4 activity declines measurably after age 60, making substrate competition more clinically relevant in geriatric patients even when the interaction is mild in younger adults.

Finasteride, Benzodiazepines, and Alcohol: The Triple Overlap

Adding alcohol to this combination introduces genuine risk. Ethanol is a CNS depressant that enhances GABA-A receptor activity through a mechanism partially overlapping with both benzodiazepines and the neurosteroids that finasteride depletes. The concern is additive or synergistic CNS depression.

The NIAAA's clinician guide on alcohol-medication interactions documents that benzodiazepines combined with alcohol increase the risk of respiratory depression, oversedation, and death. Finasteride alone does not cause respiratory depression. But the reduction in allopregnanolone may alter subjective alcohol sensitivity in ways that are poorly characterized. A preclinical study by VanDoren et al. in the Proceedings of the National Academy of Sciences showed that alcohol's behavioral effects are partially mediated through neurosteroid synthesis, suggesting finasteride could modify the sedative profile of alcohol indirectly.

Patients taking finasteride and a benzodiazepine should be counseled to avoid or strictly limit alcohol. This is standard benzodiazepine counseling, but the finasteride component adds a pharmacodynamic wrinkle that makes the advice more pressing.

Monitoring Recommendations for Co-Prescribed Patients

Routine therapeutic drug monitoring is not required for this combination. No guideline from the Endocrine Society or the American Urological Association recommends serum level checks for finasteride in the setting of benzodiazepine use.

The monitoring that does matter is clinical. Prescribers should assess for three things at follow-up visits. First, new or worsening depressive symptoms, since both finasteride (through neurosteroid reduction) and benzodiazepines (through dependence-related mood effects) can independently contribute to depression. Second, changes in anxiety severity that might prompt benzodiazepine dose escalation, because finasteride's reduction of allopregnanolone could blunt endogenous anxiolysis. Third, sedation patterns, particularly in older patients or those on CYP3A4-substrate benzodiazepines.

A reasonable monitoring schedule includes a mood and sedation check at 4 weeks after starting the combination, then every 3 months during the first year. The PHQ-9 validated depression screener takes under 2 minutes and provides a quantitative baseline.

Dose Adjustment Guidance

No dose reduction of either drug is standard practice for this combination. The FDA labels for both finasteride and common benzodiazepines do not specify dose modifications when co-prescribed.

Two exceptions deserve mention. In patients with hepatic impairment (Child-Pugh B or C), both drug classes show prolonged clearance. Finasteride's half-life extends in liver disease, and benzodiazepine accumulation risk increases. The American Geriatrics Society Beers Criteria recommend avoiding benzodiazepines entirely in older adults when possible, irrespective of finasteride status, due to fall risk and cognitive impairment.

The second exception is patients who are also taking a known strong CYP3A4 inhibitor (e.g., clarithromycin, ketoconazole, or protease inhibitors). In that three-drug scenario, the CYP3A4 inhibitor, not finasteride, drives the benzodiazepine level increase. The combination of finasteride plus a CYP3A4-substrate benzodiazepine plus a strong CYP3A4 inhibitor could produce clinically meaningful sedation even though the finasteride-benzodiazepine pair alone would not.

Patient Counseling Points

Direct patient counseling for this drug combination should cover five areas. Do not stop either medication abruptly without consulting a prescriber, since benzodiazepine discontinuation requires a taper and finasteride discontinuation leads to DHT rebound within 14 days. Report new mood changes, especially if they emerge within the first 8 weeks of starting finasteride. Avoid alcohol or limit intake to one standard drink per occasion. Do not drive or operate heavy machinery until you know how the combination affects you personally. Keep all follow-up appointments for monitoring.

The FDA MedWatch system accepts patient-reported adverse events. Patients who experience unexpected sedation, cognitive slowing, or mood disturbance on the combination should be encouraged to file a report, as post-market surveillance depends on real-world reporting to identify signals that controlled trials may miss.

Special Populations: BPH Patients on 5 mg Finasteride

Men taking finasteride 5 mg (Proscar) for benign prostatic hyperplasia represent a distinct clinical group. They are typically older (median age in the PCPT trial was 63 years), more likely to have multiple comorbidities, and more likely to be prescribed benzodiazepines for comorbid anxiety, insomnia, or procedural sedation.

The 5 mg dose produces greater neurosteroid suppression than the 1 mg hair loss dose. In a study measuring allopregnanolone levels in men on finasteride for BPH, Traish et al. reported in the Journal of Sexual Medicine that persistent neurosteroid disruption may contribute to the constellation of symptoms grouped under the term post-finasteride syndrome. While this condition remains debated, the pharmacologic basis for GABA-A modulation changes at the 5 mg dose is established.

For BPH patients prescribed a benzodiazepine, the glucuronidation-pathway agents (lorazepam, oxazepam) remain the preferred choices. If a CYP3A4-dependent benzodiazepine is necessary, starting at the lowest effective dose with a planned reassessment at 2 to 4 weeks is a conservative but defensible approach.

Finasteride 5 mg for BPH in a man over 65 who is simultaneously prescribed alprazolam 0.5 mg three times daily warrants documentation of the interaction consideration in the medical record, even though dose adjustment may not be required.